Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma : results from the Myeloma UK (MUK) nine OPTIMUM trial
Faustini, Sian E Hall, Andrew Brown, Sarah Roberts, Sadie Hill, Harriet Stamataki, Zania Jenner, Matthew W Owen, Roger G Pratt, Guy
Cook, Gordon
Faustini, Sian E
Hall, Andrew
Brown, Sarah
Roberts, Sadie
Hill, Harriet
Stamataki, Zania
Jenner, Matthew W
Owen, Roger G
Cook, Gordon
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2023-03-09
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Multiple myeloma (MM) and anti-MM therapy cause profound immunosuppression, leaving patients vulnerable to coronavirus disease 2019 (COVID-19) and other infections. We investigated anti-severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) antibodies longitudinally in ultra-high-risk patients with MM receiving risk-adapted, intensive anti-CD38 combined therapy in the Myeloma UK (MUK) nine trial. Despite continuous intensive therapy, seroconversion was achieved in all patients, but required a greater number of vaccinations compared to healthy individuals, highlighting the importance of booster vaccinations in this population. Reassuringly, high antibody cross-reactivity was found with current variants of concern, prior to Omicron subvariant adapted boostering. Multiple booster vaccine doses can provide effective protection from COVID-19, even with intensive anti-CD38 therapy for high-risk MM.
Citation
Faustini SE, Hall A, Brown S, Roberts S, Hill H, Stamataki Z; (PITCH) consortium; Jenner MW, Owen RG, Pratt G, Cook G, Richter A, Drayson MT, Kaiser MF, Heaney JLJ. Immune responses to COVID-19 booster vaccinations in intensively anti-CD38 antibody treated patients with ultra-high-risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial. Br J Haematol. 2023 Jun;201(5):845-850. doi: 10.1111/bjh.18714. Epub 2023 Mar 9.
Type
Article